Ask AI
Advances in mCRPC

CE / CME

Advances in Metastatic Castration-Resistant Prostate Cancer: Biomarker-Driven Treatment Strategies and Emerging Therapeutic Approaches

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit™

Released: July 20, 2026

Expiration: January 19, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer. v.5.2026. nccn.org.
  2. Armstrong AJ, Morris MJ, Antonarakis ES, et al. Trial design and objectives for prostate cancer: Recommendations from the Prostate Cancer Clinical Trials Working Group 4 (PCWG4). J Clin Oncol. 2026;44(7_suppl):162.
  3. Capivasertib [prescribing information]. Wilmington, DE: AstraZeneca; 2025.
  4. Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34:1652-1659.
  5. Freedland SJ, Davis MM, Epstein AJ, et al. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2024;27:327-333.
  6. Shore ND, Craver C, Blanc S, et al. Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium. January 25-27, 2024. Abstract 210.
  7. Olaparib [prescribing information]. Wilmington, DE: AstraZeneca; 2025.
  8. Rucaparib [prescribing information]. Vienna, Austria: pharmaand GmbH; 2025.
  9. Niraparib and abiraterone acetate [prescribing information]. Horsham, PA: Janssen Biotech; 2023.
  10. Talazoparib [prescribing information]. New York, NY: Pfizer; 2025.
  11. Clarke NW, Armstrong AJ, Oya M, et al. Efficacy and safety of olaparib plus abiraterone versus placebo plus abiraterone in the first-line treatment of patients with asymptomatic/mildly symptomatic and symptomatic metastatic castration-resistant prostate cancer: analyses from the phase 3 PROpel trial. Eur Urol Oncol. 2025;8:394-406.
  12. Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025;406:447-460.
  13. Chi KN, Castro E, Attard G, et al. Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the phase 3 MAGNITUDE trial. Eur Urol Oncol. 2025;8:986-998.
  14. Radium-223 [prescribing information]. Whippany, NJ: Bayer Healthcare Pharmaceuticals. Inc; 2019.
  15. Hoskin P, Sartor O, O’Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397-1406.
  16. Gillessen S, Choudhury A, Saad F, et al. A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3. Presented at: 2024 European Society for Medical Oncology Annual Conference. September 13-17, 2024. Abstract LBA1.
  17. Gillessen S, Tombal B, Turco F, et al. Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333/PEACE-3 trial comparing radium-223 combined with enzalutamide versus enzalutamide alone: a safety analysis. Eur Urol. 2025;87:285-288.
  18. Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103.
  19. Lutetium-177-PSMA-617 [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc; 2025.
  20. ‌Morris MJ, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227-1239.
  21. Crabb SJ, Griffiths G, Dunkley D, et al. Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial. Eur Urol. 2022;82:512-515.
  22. Fizazi K, Clarke NW, De Santis M, et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026;37:53-68.
  23. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624-629.
  24. Kung PP, Rui E, Bergqvist S, et al. Optimization of orally bioavailable enhancer of zeste homolog 2 inhibitors using ligand- and property-based design strategies: Identification of PF-06821497. J Med Chem. 2018;61:650-665.
  25. Schweizer MT, Calvo M, Moreno V, et al. Phase 1 trial of mevrometostat (PF-06821497), a potent and selective EZH2 inhibitor, in combination with enzalutamide in castration-resistant prostate cancer. Presented at: 2024 American Society of Clinical Oncology Annual Meeting. May 31-June 4, 2024. Abstract 5061.
  26. Schweizer MT, Calvo M, Moreno V, et al. Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer: A randomized dose-expansion study. Presented at: 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium. February 13-15, 2025. Abstract LBA138.
  27. Fizazi K, Roubaud G, Bernard-Tessier A, et al. Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results. Presented at: 2024 European Society for Medical Oncology Annual Conference. September 13-17, 2024. Abstract 1605P.
  28. Rathkopf DE, Patel MR, Choudhury AD, et al. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025;36:76-88.
  29. Chi KN, McKay RR, Sandhu S, et al. rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC. Fut Oncol. 2025;21:1771-1777.
  30. Petrylak DP, McKean M, Lang JM, et al. ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study. Presented at: 2024 American Society of Clinical Oncology Annual Conference. May 31-June 4, 2024. Abstract 5011.